- Home
- CIB vs STVN Comparison
CIB vs STVN Comparison
Compare CIB & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIB
- STVN
- Stock Information
- Founded
- CIB 1945
- STVN 1949
- Country
- CIB Colombia
- STVN Italy
- Employees
- CIB N/A
- STVN N/A
- Industry
- CIB Commercial Banks
- STVN Containers/Packaging
- Sector
- CIB Finance
- STVN Consumer Discretionary
- Exchange
- CIB Nasdaq
- STVN Nasdaq
- Market Cap
- CIB 7.6B
- STVN 6.2B
- IPO Year
- CIB 1995
- STVN 2021
- Fundamental
- Price
- CIB $32.35
- STVN $22.22
- Analyst Decision
- CIB Strong Sell
- STVN Buy
- Analyst Count
- CIB 3
- STVN 6
- Target Price
- CIB $33.67
- STVN $27.50
- AVG Volume (30 Days)
- CIB 212.5K
- STVN 328.8K
- Earning Date
- CIB 02-18-2025
- STVN 03-06-2025
- Dividend Yield
- CIB 9.99%
- STVN 0.25%
- EPS Growth
- CIB N/A
- STVN N/A
- EPS
- CIB 1.51
- STVN 0.48
- Revenue
- CIB $5,143,377,225.00
- STVN $1,220,254,294.00
- Revenue This Year
- CIB N/A
- STVN $3.01
- Revenue Next Year
- CIB $3.23
- STVN $7.07
- P/E Ratio
- CIB $5.51
- STVN $48.10
- Revenue Growth
- CIB 3.66
- STVN 3.53
- 52 Week Low
- CIB $30.25
- STVN $16.56
- 52 Week High
- CIB $37.85
- STVN $34.73
- Technical
- Relative Strength Index (RSI)
- CIB 50.45
- STVN 50.77
- Support Level
- CIB $31.78
- STVN $21.42
- Resistance Level
- CIB $33.14
- STVN $24.38
- Average True Range (ATR)
- CIB 0.54
- STVN 1.28
- MACD
- CIB 0.01
- STVN -0.12
- Stochastic Oscillator
- CIB 59.49
- STVN 42.32
About CIB BanColombia S.A.
BanColombia SA is a financial services company. A conglomerate of financial institutions, BanColombia offers a wide range of product offerings and financial services, including loans to small and midsize enterprises and governments, leasing, factoring, and asset management. The company's operations are in Colombia, Panama, El Salvador, the United States of America, Puerto Rico, Bermuda, and Guatemala.
About STVN Stevanato Group S.p.A.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.